ERAS Stock Analysis: Erasca | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 6.300m USD | 12M Return: 1161% | US29479A1088 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 74.4M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with cancers driven by the RAS/MAPK signaling pathway. The companys pipeline includes ERAS-0015, a pan-RAS molecular glue; ERAS-4001, a pan-KRAS inhibitor; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody. All three candidates target RAS-mutated or RAS/MAPK-related solid tumors.
Erasca pursues its pipeline primarily through licensing and collaboration agreements with partners including Guangzhou Joyo Pharmatech, Medshine Discovery, Novartis Pharma AG, NiKang Therapeutics, and Asana BioSciences, covering development, manufacturing, and commercialization rights for several of its programs. The company also has a clinical trial collaboration and supply agreement with Tango Therapeutics to evaluate ERAS-0015. As a clinical-stage biotechnology company, Erasca has no approved products on the market and depends on these partnerships and external capital to fund its research and development activities.
The company was incorporated in 2018 and is headquartered in San Diego, California. It is classified within the biotechnology sub-industry of the health care sector, where precision oncology has emerged as a key area of investment due to advances in genomic profiling and the prevalence of RAS pathway mutations across many solid tumor types.
- Naporafenib SEACRAFT-2 NRAS melanoma phase 3 data readout approaches
- Pan-RAS and pan-KRAS candidates face crowded competitive landscape
- Cash runway narrows as R&D spending accelerates
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.54 > 0.02 and ΔFCF/TA -26.66 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.20 > 3% & CFO -91.3m > Net Income -277.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (304.3m) vs 12m ago 7.43% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.89%; Δ -0.89% > 0%) |
| Interest Coverage Ratio: -84.21 > 6 (EBIT TTM -273.8m / Interest Expense TTM 3.25m) |
| A: 0.49 (Total Current Assets 253.8m - Total Current Liabilities 26.7m) / Total Assets 461.2m |
| B: -2.33 (Retained Earnings -1.08b / Total Assets 461.2m) |
| C: -0.59 (EBIT TTM -273.8m / Avg Total Assets 466.2m) |
| D: 5.81 (Book Value of Equity 393.5m / Total Liabilities 67.7m) |
| Altman-Z'' = -2.22 = D |
As of August 09, 2026, the stock is trading at USD 18.41 with a total of 2,052,999 shares traded. Over the past week, the price has changed by +1.43%, over one month by +0.27%, over three months by +77.02% and over the past year by +1160.96%.
Current recommended Stop Loss: 16.10 (which is 12.5% or 2 ATR below the current price).
Erasca has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy ERAS.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.8 | 23.8% |
P/B = 16.0099
Revenue TTM = 0.0 USD
EBIT TTM = -273.8m USD
EBITDA TTM = -270.8m USD
Long Term Debt = 40.7m USD (estimated: total debt 46.0m - short term 5.25m)
Short Term Debt = 5.25m USD (from shortTermDebt, last quarter)
Debt = 46.0m USD (from shortLongTermDebtTotal, last quarter) (leases 46.0m already included)
Net Debt = -197.8m USD (calculated: Debt 46.0m - CCE 243.8m)
Enterprise Value = 6.10b USD (6.30b + Debt 46.0m - CCE 243.8m)
Interest Coverage Ratio = -84.21 (Ebit TTM -273.8m / Interest Expense TTM 3.25m)
EV/FCF = -24.66x (Enterprise Value 6.10b / FCF TTM -247.4m)
FCF Yield = -4.05% (FCF TTM -247.4m / Enterprise Value 6.10b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.11m) / Revenue TTM)
Tobins Q-Ratio = 13.23 (Enterprise Value 6.10b / Total Assets 461.2m)
Interest Expense / Debt = 7.07% (Interest Expense 3.25m / Debt 46.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -216.3m (EBIT -273.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.80 (Total Current Assets 253.8m / Total Current Liabilities 28.8m)
Debt / Equity = 0.12 (Debt 46.0m / totalStockholderEquity, last quarter 393.5m)
Debt / EBITDA = 0.73 (negative EBITDA) (Net Debt -197.8m / EBITDA -270.8m)
Debt / FCF = 0.80 (negative FCF - burning cash) (Net Debt -197.8m / FCF TTM -247.4m)
Total Stockholder Equity = 359.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.42% (Net Income -277.0m / Total Assets 461.2m)
RoE = -77.01% (Net Income TTM -277.0m / Total Stockholder Equity 359.7m)
RoCE = -68.37% (EBIT -273.8m / Capital Employed (Equity 359.7m + L.T.Debt 40.7m))
RoIC = -49.17% (negative operating profit) (NOPAT -216.3m / Invested Capital 439.8m)
WACC = 11.74% (E(6.30b)/V(6.35b) * Re(11.78%) + D(46.0m)/V(6.35b) * Rd(7.07%) * (1-Tc(0.21)))
Discount Rate = 11.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.51 | Cagr: 50.90%
[DCF] Fair Price = unknown (Cash Flow -247.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.11 | Chg30d=+3.46% | Revisions=-40% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=+3.00% | Revisions=-50% | Analysts=9
EPS current Year (2026-12-31): EPS=-0.95 | Chg30d=+1.34% | Revisions=-70% | GrowthEPS=-116.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.55 | Chg30d=+3.76% | Revisions=-30% | GrowthEPS=+42.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -68% (up=2, down=17)